clinical trial · NCT07641855
A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer
Sichuan Baili Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 180
Castration-resistant Prostate CancerBL-B01D1AbirateroneOlaparib
brief summary
This study will first conduct a phase II clinical study, and on the basis of the phase II clinical study, subsequent clinical research will be carried out.
started
Jun 1, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Jun 11, 2026
official title
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol